AtriCure

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AtriCure excels in 2022, eyes growth in cardiac surgery market

AtriCure's strong performance in 2022 sets the stage for continued growth and profitability.
Focus on technological advancements and clinical trials to drive future revenue growth.
Addressing challenges like slower adoption and macro pressures with strategic planning.
Positioned for success with a robust product portfolio and international growth prospects.

AtriCure reports robust Q1 earnings, eyes growth amid competition

AtriCure's Q1 2023 performance was strong, with revenue growth and a focus on profitability. Challenges include cash burn and potential competition in the cryoSPHERE market. The company's innovative approach and growth projections offer promising opportunities.

AtriCure posts robust Q2 results, eyes international growth opportunities

AtriCure's Q2 performance showcased strong revenue growth, margin improvement, and strategic acquisitions, positioning the company for continued success.
While challenges like ongoing investments and product optimization exist, opportunities in international markets, acquisitions, and cardiac surgery trends offer avenues for future growth.
The company's focus on clinical trials, long-term market opportunities, and maintaining a strong balance sheet underscores its commitment to innovation and sustainable growth.

AtriCure (ATRC) reports robust Q3 earnings, eyes growth opportunities

AtriCure's strong Q3 performance and positive outlook for full year 2023 demonstrate growth potential across key franchises. Challenges include market transitions impacting pain management growth and the need to adapt to evolving market dynamics. Opportunities lie in new product launches, clinical trials, and market expansion strategies.

AtriCure reports robust Q4 growth, eyes new products and market opportunities

AtriCure's strong financial performance in Q4 2023 and expectations of 15-17% revenue growth in 2024 showcase sustained momentum.
The company's focus on innovation, product adoption, and market opportunities positions it well for future expansion and impact.
Balancing challenges like product development and market dynamics with pricing strength and operational efficiency will be key for continued success.

AtriCure excels in Q1 2024, eyes global impact with innovations

AtriCure's strong start in 2024 driven by revenue and EBITDA growth.
Focus on innovation, clinical trials, and international expansion.
Challenges include product adoption and R&D investment balance.
Opportunities lie in market leadership, new product launches, and global trials.

AtriCure posts strong Q2 results, eyes EU expansion and trial completion

AtriCure's Q2 2024 performance reflects robust revenue growth and positive EBITDA, driven by key franchise expansions and clinical trials.
While facing challenges such as increased operating expenses and a loss per share, the company maintains a focus on innovation and growth opportunities.
Revised full-year guidance and strategic product launches position AtriCure for continued growth and market leadership in the medical device sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today published its inaugural Environmental, Social and Governance (ESG) report highlighting the company's corporate responsibility and sustainability initiatives. AtriCure's 2021 ESG Report showcases several of the company's recent ESG accomplishments, including: Achieving

AtriCure Publishes Inaugural ESG Report

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 11th Annual SVB Leerink Global Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, February 16, 2022, at 8:40 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “I

AtriCure to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 15, 2022 to discuss its fourth quarter and full year 2021 financi

AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2021 and provided 2022 financial guidance. Preliminary, unaudited revenue for fourth quarter 2021 is expected to be approximately $73.2 million, reflecting growth of approximately 27% over the fou

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference. AtriCure's management is scheduled to present on Monday, January 10, 2022, at 7:30 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” s

AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. AtriCure's prerecorded fireside chat will be available on Monday, November 22, 2021 on the conference and company's website. Interested parties may access a live audio webcast of the presentat

AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2021 Results - Earnings Call Transcript

AtriCure (ATRC) delivered earnings and revenue surprises of 739.39% and 2.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Tops Q3 Earnings and Revenue Estimates

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results. “Our results were driven by strong growth across key product lines, including the addition of new Cryo Nerve Block and Hybrid AF™ Therapy accounts, providing further validation of demand across our business,” said Michael Carrel, President and Chief Executive Officer of Atri

AtriCure Reports Third Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, November 3, 2021 to discuss its third quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for d

AtriCure to Announce Third Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference. AtriCure's management is scheduled to present on Tuesday, September 14, 2021, at 11:45 a.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by

AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

AtriCure's (ATRC) CEO Mike Carrel on Q2 2021 Results - Earnings Call Transcript

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by outperformance across our business, as strong underlying demand returned and we saw continued progress toward making our platforms the standard of care,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We a

AtriCure Reports Second Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference. AtriCure's management is scheduled to present on Wednesday, August 11, 2021, at 8:00 a.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by visiting the “Inv

AtriCure to Participate at the Canaccord 41st Annual Growth Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 4, 2021 to discuss its second quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for dom

AtriCure to Announce Second Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms. Telman has spent over 20 years in senior executive roles at global companies. She is Executive Vice President and General Counsel for Organon (NYSE: OGN), a global healthcare company formed in June 2021 through a spinoff from

AtriCure Names Two New Members to the Board of Directors

Advanced Micro Devices

Amedisys

Deere & Company

Zscaler

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Deere & Advanced Micro Devices.

These are Wall Street's top analysts favorite stocks heading into June

AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock?

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. Food and Drug Administration (FDA) approval of the EPi-Sense® System to treat patients diagnosed with long-standing persistent Afib. The CONVERGE™ trial demonstrated superiority in the hybrid AF™ therapy arm compared to endocardial catheter ablation alone. In patients diagnosed with long-standing persistent

AtriCure's EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients

AtriCure, Inc.'s (ATRC) CEO Mike Carrel on Q1 2021 Results - Earnings Call Transcript

Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 11.11% year over year to ($0.32), which beat the estimate of ($0.37).

AtriCure: Q1 Earnings Insights

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results. “Our growth in the first quarter is a testament of our team's strong execution and unwavering dedication despite continued COVID headwinds,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “As we navigate toward a return to normalcy, I am confident th

AtriCure Reports First Quarter 2021 Financial Results

AtriCure (NASDAQ:ATRC) announces its next round of earnings this Tuesday, April 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.

Preview: AtriCure's Earnings

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair. In addition, the Company announced that Scott Drake and Mark Lanning will not stand for re-election at the end of their terms in May 2021. “Kris' experience and counsel have been impactful to AtriCure over the past four years, and I'm delighted that she

AtriCure Names B. Kristine Johnson Board Chair

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, April 27, 2021 to discuss its first quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domes

News for AtriCure Stock (ATRC)